EUVIMEDEUVIMED entdecken
Crossref

Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer

Taichiro Goto

AME Clinical Trials Review · 2023

DOI: 10.21037/actr-23-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AME Clinical Trials Review, 2023. Verfasst von Taichiro Goto.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Goto, T. (2023). Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-24

Vancouver

Goto T. Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer. AME Clinical Trials Review. 2023. doi:10.21037/actr-23-24

BibTeX
@article{Goto2023,
  author = {Goto, Taichiro},
  title = {Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer},
  journal = {AME Clinical Trials Review},
  year = {2023},
  doi = {10.21037/actr-23-24}
}
Kostenlos starten →